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(SOT) recipients. Among Swiss SOT recipients, we assessed temporal trends of ESBL-producing Enter-
obacterales (ESBL-E), identified risk factors for ESBL-E, and assessed the impact of resistance on patient
outcome. METHODS Data from the Swiss Transplant Cohort Study (STCS), a nationwide prospective
cohort of SOT-recipients, were analysed. Temporal trends were described for ESBL-detection among
Escherichia coli and non-Escherichia coli. In a nested case-control study, cases with ESBL-E infection
were 1:1 matched (by time since transplantation, organ transplant, pathogen) to controls infected with
non-ESBL-E. Factors associated with resistance and with unfavourable 30-day outcome (death, infection
relapse, graft loss) were assessed. RESULTS From 2012 to 2018, we identified 1’212 infection episodes
caused by Enterobacterales in 1’074 patients, thereof 11.4% (138/1’212) caused by ESBL-E. The propor-
tion of ESBL-production among Escherichia coli remained stable over time (p = 0.93) but increased for
non-E. coli (p = 0.02) Enterobacterales. In the case-control study (n = 102), antibiotic pre-treatment was
independently associated with ESBL-production (aOR = 2.6, 95%-CI: 1.0-6.8, p = 0.046). Unfavourable
outcome occurred in 24/51 (47%) cases and 9/51 (18%) controls (p = 0.003). Appropriate empiric an-
tibiotic therapy was the only modifiable factor associated with unfavourable outcome. CONCLUSIONS
In Swiss SOT-recipients, proportion of infections with ESBL-producing non-E. coli Enterobacterales
increased in recent years. Antibiotic pre-treatment represents a risk factor for ESBL-E. Improving ap-
propriateness of empiric antibiotic treatment might be an important measure to reduce unfavourable
outcome, which was observed in almost half of SOT-recipients with ESBL-E infections.
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of infections due to extended-spectrum 
β-lactamase producing Enterobacterales in Swiss 
solid organ transplant recipients between 2012 
and 2018
Philipp Kohler1*† , Aline Wolfensberger2†, Susanne Stampf3, Andreas Brönnimann2, Katia Boggian1, 
Christian van Delden4, Melody Favre4, Cédric Hirzel5, Nina Khanna6, Stefan P. Kuster2, Oriol Manuel7, 
Dionysios Neofytos4, Silvio Ragozzino6, Peter W. Schreiber2, Laura Walti5 and Nicolas J. Mueller2Swiss Transplant 
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Abstract 
Background: The burden of antimicrobial resistance is high in solid organ transplant (SOT) recipients. Among Swiss 
SOT recipients, we assessed temporal trends of ESBL-producing Enterobacterales (ESBL-E), identified risk factors for 
ESBL-E, and assessed the impact of resistance on patient outcome.
Methods: Data from the Swiss Transplant Cohort Study (STCS), a nationwide prospective cohort of SOT-recipients, 
were analysed. Temporal trends were described for ESBL-detection among Escherichia coli and non-Escherichia coli. 
In a nested case–control study, cases with ESBL-E infection were 1:1 matched (by time since transplantation, organ 
transplant, pathogen) to controls infected with non-ESBL-E. Factors associated with resistance and with unfavourable 
30-day outcome (death, infection relapse, graft loss) were assessed.
Results: From 2012 to 2018, we identified 1′212 infection episodes caused by Enterobacterales in 1′074 patients, 
thereof 11.4% (138/1′212) caused by ESBL-E. The proportion of ESBL-production among Escherichia coli remained 
stable over time (p = 0.93) but increased for non-E. coli (p = 0.02) Enterobacterales. In the case–control study (n = 102), 
antibiotic pre-treatment was independently associated with ESBL-production (aOR = 2.6, 95%-CI: 1.0–6.8, p = 0.046). 
Unfavourable outcome occurred in 24/51 (47%) cases and 9/51 (18%) controls (p = 0.003). Appropriate empiric antibi-
otic therapy was the only modifiable factor associated with unfavourable outcome.
Conclusions: In Swiss SOT-recipients, proportion of infections with ESBL-producing non-E. coli Enterobacterales 
increased in recent years. Antibiotic pre-treatment represents a risk factor for ESBL-E. Improving appropriateness of 
empiric antibiotic treatment might be an important measure to reduce unfavourable outcome, which was observed 
in almost half of SOT-recipients with ESBL-E infections.
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Introduction
Antimicrobial resistance is a major threat to the achieve-
ments of modern medicine. Solid organ transplant (SOT) 
recipients are at particular risk for acquisition of resistant 
pathogens, most likely due to increased healthcare and 
antibiotic exposure [1]. Specifically in SOT-recipients, 
donor-derived infections due to resistant pathogens are 
associated with significant burden of disease [2]. Over 
the last decade, Gram-negative bacteria have become 
the focus of attention regarding antibiotic resistance for 
both the general hospital population and SOT-recipients. 
A recent systematic review reported that 20% of SOT-
recipients are colonized with ESBL-producing Escheri-
chia coli [3]. Colonization by ESBL-producing isolates 
is an important risk factor for subsequent infection [4]; 
about one in 10 renal transplant recipients (RTR) colo-
nized by ESBL-producing bacteria experiences a urinary 
tract infection (UTI) caused by these pathogens [5]. 
Compared to infections with non-resistant pathogens, 
those caused by resistant bacteria are associated with an 
increased risk for recurrent infection, allograft dysfunc-
tion and excess mortality [5, 6]. Case-fatality infection 
with resistant pathogens is high (up to 50% in the case 
of bacteremia due to carbapenem-resistant Enterobacte-
rales) [7–9].
Among Swiss SOT recipients, most infections in the 
first year post-transplantation are caused by Entero-
bacterales. Among E. coli and Klebsiella pneumoniae, 
ESBL-production was observed in 15%, whereas no 
carbapenemase-producing Enterobacterales (CPE) were 
identified in our cohort [10]. Here, we aimed to assess 
temporal trends of ESBL-producing Enterobacterales 
(ESBL-E), to identify risk factors for infections with 




The Swiss Transplant Cohort Study (STCS) is a nation-
wide, multi-centre, open, prospective cohort and has 
enrolled all SOT-recipients in Switzerland since May 
2008 [11]. Clinical and laboratory data are prospec-
tively collected at the time of transplantation, at 6 and 
12  months, and annually thereafter. Infectious epi-
sodes are identified by transplant infectious disease (ID) 
physicians on a regular basis using electronic patient 
records, according to definitions developed by the STCS 
infectious diseases working group [10]. Six participating 
transplantation centres (Basel, Bern, Geneva, Lausanne, 
St. Gallen and Zurich) undergo regular data monitoring 
and in-depth data quality audits.
Study design and participants
We included SOT-recipients of heart, liver, kidney, and 
kidney-pancreas grafts aged 18 or older enrolled in the 
STCS. Lung transplant recipients were excluded because 
of the particular challenge to distinguish colonisation 
from infection in this population. From August 2012 
onwards, information about ESBL production has been 
available in the STCS database. For the analysis of tem-
poral trends, we thus retrieved all infection episodes 
diagnosed between August 2012 and December 2018. 
Participants contributed a maximum of one episode per 
year. Those with episodes caused by resistant and suscep-
tible pathogens were counted as having had one resistant 
episode and were not eligible as controls. Patients with 
episodes caused by ESBL-producing E. coli and non-E. 
coli Enterobacterales in the same year were counted in 
both groups.
A nested case–control study was performed to assess 
risk factors for infection by ESBL-E and its effect on 
90-day outcome afterwards. As opposed to the analy-
sis for temporal trends (episode level) this analysis 
was performed on the patient-level (i.e. only one epi-
sode per patient considered). We included all patients 
with infections due to ESBL-producing (or MDR and 
extended-spectrum cephalosporine-resistant, see below) 
Enterobacterales, diagnosed between August 2012 and 
December 2016. In case of multiple episodes caused by 
a resistant pathogen, only the patients’ first episode after 
transplantation was considered. Cases were matched to 
controls in a 1:1 fashion, applying incidence density sam-
pling according to time to first infectious episode after 
transplantation; type of transplanted organ and bacte-
rial pathogen were used as further matching criteria. 
Controls with previous colonization by ESBL-E were 
excluded. Detailed information about infections in cases 
and controls were additionally collected via chart review 
and recorded in an electronic database (SecuTrial®). 
These included administration of antibiotics within 
30  days before infection (both therapeutic and prophy-
lactic), travel history, urinary obstruction (only for RTR), 
admission to acute or intensive care, involvement of ID 
specialist, type, duration and effectiveness of empiric and 
definite antibiotic treatment, and 90-day outcome.
Keywords: Solid organ transplant, Renal transplant, Extended-spectrum beta-lactamase, Enterobacterales, 
Switzerland
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Microbiology
Pathogen identification and resistance testing was per-
formed on a routine basis in the microbiology labo-
ratories serving the participating centres. Since 2012, 
information about infections caused by ESBL-E is being 
recorded. Also, the presence of multidrug-resistance 
(MDR) is recorded according to the European Centre for 
Disease Prevention and Control (ECDC) definitions [12]. 
For the analysis of temporal trends, the variable “ESBL-
production” as reported in the database was used to 
classify resistant and susceptible pathogens. For the 
case–control study, this definition was extended to also 
include MDR pathogens with resistance to extended-
spectrum cephalosporins (ESC), i.e. 3rd or 4th genera-
tion cephalosporins. This approach was chosen because 
for some bacterial isolates ESBL-production was not 
tested or reported.
Definitions
In brief, proven infection was defined as the presence of 
clinical signs or symptoms, detection of a bacterial path-
ogen, and given treatment [10]. Effectiveness of antibiotic 
treatment was assessed according to locally performed 
susceptibility tests. Beta-lactam/beta-lactamase inhibitor 
combinations were considered inadequate against ESBL-
E irrespective of the reported minimal inhibitory con-
centration. Unfavourable outcome was defined as any of 
the following: microbiological relapse (i.e. infection with 
the same pathogen at same body site as the initial infec-
tious episode), graft failure (defined as dialysis post renal 
transplantation; or re-transplantation post heart or liver 
transplantation; or recurrence of insulin-dependence fol-
lowing pancreas transplant) or death, all within 90 days 
after infection.
Statistical analysis
A temporal trend analysis was performed to detect a 
pattern in occurrence of infectious episodes caused by 
ESBL-producing E. coli and non-E. coli Enterobacte-
rales between 2012 and 2018, using Chi-squared test 
for trends in proportion. In the matched subpopulation 
(including episodes which occurred between 2012 and 
2016), a descriptive analysis was done followed by uni-
variate and multivariable conditional logistic regression 
to evaluate risk factors for infections caused by ESBL-E. 
Age and gender, as well as baseline characteristics associ-
ated with ESBL-E infection in univariate analysis (p < 0.1) 
were included in the multivariable model. Multicollinear-
ity was assessed calculating the variance inflation factor 
(cut-off > 10).
For the analysis regarding impact of resistance 
on patient outcome, infection by ESBL-E itself was 
considered a key predictor. We used the change in esti-
mate method as screening method for selection of co-
variables into the multivariable logistic regression model 
(i.e. change of key predictor estimate > 10% after add-
ing the co-variable to the model) [13]. R software ver-
sion 3.6.1 was used for all statistical analyses; a p value 
of < 0.05 was considered statistically significant.
Results
Temporal trends
Between 2012 and 2018, we registered 1′212 infec-
tious episodes caused by Enterobacterales among 1′074 
patients, mostly among RTR (784/1′074, 73%). Among 
all isolates, ESBL-production was reported in 138/1′212 
isolates (11.4%). ESBL rates for episodes of kidney, heart, 
and liver transplant patients were 13.2% (168/1271), 
12.4% (11/89), and 13.6% (30/221), respectively; across 
the six participating centres, the proportion of ESBL-
producing isolates ranged from 8.3 to 18.3%. The propor-
tion of ESBL E. coli remained stable over time (p = 0.93) 
whereas an increasing trend (p = 0.024) was observed for 
non-E. coli Enterobacterales (Fig.  1). No temporal trend 
was observed when ESBL E. coli and non-E. coli were 
combined (p = 0.36).
Case–control study: population and infection 
characteristics
Between 2012 and 2016, we identified 88 case patients 
which were matched to 88 controls. After chart review 
and revision of the original susceptibility test results, 
51 matching pairs remained for the analysis. For the 37 
excluded patients, reasons for exclusion were mostly lim-
ited or missing susceptibility testing (15/37) and revision 
of case status (14/37). Of the 51 cases and controls, 33 
(65%) were RTR, 4 (8%) kidney-pancreas, 9 (18%) liver 
or kidney-liver, and 5 (10%) heart transplant patients, 
respectively. The urinary tract was the most common site 
of infection (75%). E. coli was the most frequent pathogen 
found in infections (75.5%), followed by K. pneumoniae 
(15.7%) and other pathogens (8.8%).
Baseline characteristics of cases and controls were 
summarized in Table  1. Infections occurred a median 
of 69  days after transplant (interquartile range [IQR]: 
25–232), mostly (68%) within the first 6  months after 
transplantation (Fig.  2). Patients were predominantly 
outpatients at time of diagnosis (63% for ESBL-E, 61% for 
non-ESBL-E infections). ESBL-E and non-ESBL-E infec-
tions were evenly distributed among centres and years, as 
were infection sites and comorbidities. Travel history was 
not available for most patients and therefore dropped 
from further analyses.
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Risk factors for ESBL infection
Male gender (p = 0.04) and antibiotic treatment within 
30  days prior to infection (p = 0.05) were significantly 
associated with ESBL-E infection (Table  2). Antibiotic 
pre-treatment remained as independent risk factor for 
ESBL-E infection in multivariable analysis after correc-
tion for age, gender and underlying metabolic/endo-
crinologic disease (adjusted OR = 2.6, 95% CI: 1.0–6.8, 
p = 0.046).
Infection management and outcome
Patients with susceptible and resistant pathogens were 
similar in terms of proportion of hospital admission 
(16/51 vs. 14/51), intensive care admission (9/51 vs. 8/51), 
or involvement of an ID physician for choice of treatment 
(22/51 vs. 27/51) (Table 3). Length of stay was longer for 
those with resistant (median 18  days, IQR 8.2–30  days) 
vs. those with susceptible pathogens (median 9, IQR 
3–24  days), but did not reach statistical significance 
(p = 0.10). Patients with susceptible pathogens were more 
likely to receive appropriate empiric antibiotic therapy 
(36/51, 76%) vs. those with resistant pathogens (16/51, 
36%) (p < 0.001). Inappropriate therapy was mostly due 
to late initiation (i.e. > 2 days after infection) of antibiotic 
therapy (similar in both groups: 8/51 vs. 11/51, p = 0.44), 
or due to administration of beta-lactam/beta-lactamase 
inhibitors against resistant pathogens (1/51 vs. 10/51, 
p = 0.004).
Unfavourable outcome occurred in 9/51 (18%) con-
trols with non-ESBL-E infections as compared to 24/51 
(47%) patients with ESBL-E infections (p < 0.003). This 
difference was mainly due to relapse of infection (5/51 vs. 
20/51, p = 0.001), whereas graft loss (4/51 vs. 1/51) and 
mortality (3/51 vs. 4/51) were similar in both groups.
Evaluating the impact of resistance on unfavourable 
outcome, infection with ESBL-E was associated with 
unfavourable (OR = 4.0, 95%-CI: 1.7–10.5, p = 0.003) and 
adequate empiric therapy (OR = 0.3, 95%-CI: 0.1–0.9, 
p = 0.03) with favourable outcome in univariate analy-
sis (Table  4). After adjusting for modifiable (adequate 
empiric therapy) and non-modifiable (gender and need 
for ICU stay after infection) factors, the effect of ESBL-
E infection was still large, but not anymore signifi-
cantly associated with unfavourable outcome (adjusted 
OR = 3.1, 95%-CI: 0.8–12.5, p = 0.10).
Discussion
In this study based on data from a prospective national 
cohort representing all SOT-recipients in Switzerland, 
we show that ESBL-producing non-E. coli infections have 
been increasing over the last years and that antibiotic 
pre-treatment is independently associated with infection 
caused by ESBL-producing pathogens. Almost half of 
patients with ESBL-E had a relapsing infection compared 
to only 18% in those with non-ESBL E infections. Ade-
quate empiric therapy, being less common among those 
with ESBL-E infection, was the only modifiable factor 
associated with unfavourable outcome. The comprehen-
sive dataset and the thorough revision of the original data 
are particular strengths of the study.
Fig. 1 Proportion of patients with ESBL-producing Escherichia coli (left) and non-E. coli (right) among all patients infected with the corresponding 
pathogen in the Swiss Transplant Cohort Study between 2012 and 2018
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The three last decades have witnessed a global dis-
semination of ESBL-producing Enterobacterales into 
healthcare systems and healthy populations alike [14]. 
From an epidemiological perspective, their emergence is 
propelled by various factors. Important drivers of com-
munity-acquisition (mostly ESBL-E. coli carrying the 
plasmid-encoded blaCTX-M gene) are travel to/health-
care in endemic countries or household crowding [15, 
Table 1 Baseline characteristics of patients infected without and with extended-spectrum beta-lactamase (ESBL)-Enterobacterales 
ESBL extended-spectrum beta-lactamase, SD standard deviation, BMI body mass index, IQR interquartile range, BL/BLI beta-lactam/beta-lactamase-inhibitor
a Previously ESBL colonized participants were not eligible for the control group
b Including prophylaxis
Cases (N = 51) Controls (N = 51)
Male, N (%) 28 (54.9%) 17 (33.3%)
Age at time of infection, mean (SD) 54.8 (12) 53.4 (14.8)
Transplanted organ (matched variable)
 Kidney 33 (64.7%) 33 (64.7%)
 Kidney-pancreas 4 (7.8%) 4 (7.8%)
 Liver (incl kidney-liver) 9 (17.6%) 9 (17.6%)
 Heart 5 (9.8%) 5 (9.8%)
BMI at transplantation, mean (SD) 25.5 (4.1) 25.1 (4.2)
Caucasian ethnicity, N (%) 46 (90.2%) 49 (96.1%)
Comorbidities, N (%)
 Cardiopulmonary disease 27 (52.9%) 25 (49%)
 Metabolic/endocrine disease 35 (68.6%) 43 (84.3%)
 Cancer 8 (15.7%) 6 (11.8%)
 Other 32 (62.7%) 31 (60.8%)
Previously documented ESBL  colonizationa 19 (37%) 0 (0%)
Antibioticsb (30 days before infection), N (%) 24 (47.1%) 14 (27.5%)
 BL/BLI 10 (37%) 6 (28.6%)
 Carbapenem 6 (22.2%) 3 (14.3%)
 Quinolone 10 (37%) 3 (14.3%)
 Cephalosporine 7 (25.9%) 0 (0%)
 Sulfamethoxazol/trimethoprim 7 (25.9%) 4 (19%)
Hospital-onset, N (%) 20 (39.2%) 19 (37.3)
Day of onset (median, IQR) 20 (9.5–60) 8 (6–42)
Days from transplantation to infection, median (IQR) 67 (24–228) 71 (33–227)
Year of 1st infection, N (%)
 2012 6 (11.8%) 8 (15.7%)
 2013 9 (17.6%) 13 (25.5%)
 2014 14 (27.5%) 12 (23.5%)
 2015 16 (31.4%) 10 (19.6%)
 2016 6 (11.8%) 8 (15.7%)
Infection site, N (%)
 Urinary tract 38 (74.5%) 39 (76.5%)
 With bacteremia 5 (13.2%) 10 (25.6%)
 Abdominal/liver 2 (3.9%) 3 (5.9%)
 Respiratory tract 3 (5.9%) 5 (9.8%)
 Surgical site 3 (5.9%) 4 (7.8%)
 Primary bacteremia 2 (3.9%) 1 (2.0%)
 Other 3 (5.9%) 1 (2.0%)
If urinary tract infection, N (%)
 Obstruction 2/38 (5.3%) 5/39 (12.8%)
 Catheter 12/38 (31.6%) 17/39 (43.6%)
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16]. In contrast, ESBL-non E. coli (mostly Klebsiella spp.) 
are often hospital-acquired, mainly as a result of clonal 
expansion due to person-to-person transmission [17]. In 
our cohort of SOT-recipients, we found stable numbers 
or ESBL-E. coli, but an increase in ESBL-non E. coli over 
time, a worrisome finding which has also been observed 
in other European SOT cohorts [18–20]. We can only 
speculate as to the reason for this trend. Increased in-
hospital transmission of these pathogens is one possi-
ble explanation, given the substantial differences in the 
prevalence of ESBL-producing Enterobacterales among 
participating centres in our study and given the many 
reports of resistant K. pneumoniae (and particularly 
high-risk clones such as ST11 or ST147) as a cause of 
nosocomial outbreaks among transplant and non-trans-
plant patients [21–24].
In both community and hospital settings, antibiotic 
treatment—mainly cephalosporins but also quinolo-
nes—is associated with ESBL-colonization or infection, 
probably due to selection (or co-selection in the case 
of quinolones) of ESBL-E in the gut flora of colonized 
patients [15, 25]. Razazi et al. found treatment with 3rd 
generation cephalosporins to be predictive of ESBL-E 
colonization in patients admitted to intensive care [26]. 
In a Canadian cohort of RTR, antibiotic pre-treatment 
was the strongest risk factor for detection of resistant 
Gram-negative bacteria in the urine [27]; in a recent 
study on enterobacterial bloodstream infections among 
SOT-recipients in the United States, antibiotic expo-
sure to trimethoprim-sulfamethoxazole and again 3rd 
generation cephalosporins were strong risk factors for 
Fig. 2 Histogram showing the time from transplant to onset of 
infection in days for 51 cases (above) and 51 controls (below)
Table 2 Univariable and multivariable conditional logistic regression analysis regarding risk of infection with ESBL-producing 
pathogen (vs. non-ESBL)
ESBL extended-spectrum beta-lactamase, (a)OR (adjusted) odds ratio, CI confidence interval, BMI body mass index
a Any therapeutic or prophylactic antibiotic treatment within 30 days prior to infection
Univariate
OR [95%-CI] (p value)
Multivariable
aOR [95%-CI] (p value)
Male versus female 2.4 [1.0–5.4] (0.04) 2.3 [0.9–5.0] (0.08)
Age (years) at time of infection 1.0 [0.9–1.0] (0.58) 0.9 [0.9–1.0] (0.99)
BMI at transplantation 1.0 [0.9–1.1] (0.92)
Caucasian versus others 0.4 [0.1–2.1] (0.27)
Comorbidities (yes/no)
 Cardiopulmonary disease 1.1 [0.6–2.3] (0.72)
 Metabolic/endocrine disease 0.5 [0.2–1.1] (0.10) 0.4 [0.2–1.1] (0.09)
 Cancer 1.4 [0.4–4.4] (0.57)
 Other 1.1 [0.5–2.7] (0.82)
Year of infection
 2012 –
 2013 1.2 [0.3–4.7] (0.83)
 2014 1.6 [0.3–7.1] (0.57)
 2015 2.5 [0.6–11.1] (0.23)
 2016 0.9 [0.2–5.3] (0.94)
Antibiotics (yes/no) before  infectiona 2.4 [1.0–5.9] (0.048) 2.6 [1.0–6.8] (0.046)
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infections with ESBL-producers [28]. We could confirm 
this important finding in our cohort of SOT-recipients. 
Due to the small sample size of the subgroups in our 
cohort, it is difficult to tell which antibiotic substances 
contributed mainly to this effect. It is important to note 
that not only cephalosporins or quinolones, but also 
beta-lactam/beta-lactamase inhibitor combinations have 
been independently associated with ESBL-Klebsiella 
spp., at least in hospitalized non-transplant patients [29]. 
Consequently, we think that antibiotic stewardship pro-
grams aiming at reducing the overall antibiotic use in this 
population is key in lowering the selection pressure for 
ESBL-E and other resistant pathogens. In this context it 
is important to note that—according to a recent survey 
among European transplant centres—a majority of trans-
plant physicians uses antibiotics including quinolones 
and cephalosporins for asymptomatic bacteriuria in RTR 
despite the uncertain benefit of this intervention [30, 31].
In general, SOT-recipients infected with resistant 
pathogens fare worse than those infected with suscepti-
ble bacteria. Delmas-Frenette et al. found resistance to be 
associated with a longer duration of antibiotic treatment 
and a higher rate of hospitalization [27]. Other stud-
ies have even reported higher case fatality rates in those 
with resistant bacterial infections [6, 7]. In our univari-
able analysis, ESBL-production was strongly associated 
with unfavourable outcome, which was mostly recurrent 
infection among RTR. Similarly, data from a systematic 
review showed that UTI recurrence was clearly more 
common among RTR infected with ESBL-E compared to 
non-ESBL-E [5]. There are different reasons which could 
explain the higher recurrence rate in those with ESBL-E 
infections. First, as shown above, ESBL-infection devel-
ops more often in those with previous antibiotic treat-
ment. This is probably the first step in a vicious circle, 
as antibiotic treatment itself might increase the risk for 
UTI recurrence which then again exposes the patient 
to antibiotic treatment [32]. Breaking this circle could 
be achieved by a reduction of antibiotic use. At least for 
the prevention of UTIs with non-antibiotic substances 
studies have shown promising results for transplant and 
non-transplant patients [33, 34]. Second, there have 
been suggestions that E. coli strains like ST131, a hyper-
endemic clone often associated with ESBL-production, 
Table 3 Management and outcome of infections caused by non-extended-spectrum beta-lactamase (ESBL)- and ESBL-producing 
Enterobacterales 
ESBL extended-spectrum beta-lactamase, IQR interquartile range, BL/BLI beta-lactam/beta-lactamase-inhibitor
a Chi-square or Fisher’s exact test for dichotomous variables, as appropriate; Mann–Whitney U for continuous variables
b Administered within two days after infection diagnosis
c Inadequate BL/BLI were all piperacillin/tazobactam except for one case who received amoxicillin/clavulanic acid
Cases (N = 51) Controls (N = 51) p  valuea
Management
Hospital admission if community onset, N (%) 14 (43.8%) 16 (50.0%) 0.99
Length of stay after infection (median, IQR) 18 (8.2–30) 9 (3–24) 0.10
On intensive care after infection onset, N (%) 8 (23.5%) 9 (25.7%) 1.00
 Days on intensive care (median, IQR) 5.5 (4–16) 3 (2–11) 0.38
Infectious diseases consult, N (%) 27 (52.9%) 22 (43.1%) 0.43
 Initially 21 (41.2%) 16 (31.4%) 0.41
 Upon microbiology results 18 (35.3%) 19 (37.3%) 1.00
Antibiotics (30 days after infection), N (%)
 Adequate empiric  therapyb 16 (35.6%) 34 (75.6%) < 0.001
 Inadequate BL/BLIc 10 (22.7%) 1 (2.3%) 0.004
 Inadequate ceftriaxone/ceftazidime 2 (4.5%) 0 (0%) 0.15
 Inadequate ciprofloxacin 5 (11.4%) 1 (2.3%) 0.09
 No therapy before day 2 11 (21.5%) 8 (18.2%) 0.44
Outcome
Re-admission, N (%) 15 (29.4%) 14 (27.5%) 1.00
 Due to infection 12 (23.5%) 8 (15.7%) 0.35
Unfavourable outcome within 90 days, N (%) 24 (47.1%) 9 (17.6%) 0.003
 Relapse 20 (39.2%) 5 (9.8%) 0.001
 Graft loss 1 (2.0%) 4 (7.8%) 0.36
 Death 4 (7.8%) 3 (5.9%) 1.00
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come along with increased virulence compared to sus-
ceptible pathogens [35]. However, in a study among 
healthy young women ST131 was not associated with 
recurrence [36]. Third, patients with resistant infections 
are less likely to receive appropriate empiric antibiotic 
therapy, as shown in our results and by others [7]. In a 
recent study on community-acquired UTI among non-
transplant patients, the higher recurrence rate among 
ESBL-E infections was primarily driven by inappropri-
ate antibiotic treatment [37]. This is in line with results 
from our multivariable analysis, showing a reduction of 
the association between ESBL and unfavourable outcome 
after adjusting for inappropriate empiric therapy. Improv-
ing appropriateness of empiric therapy in this population 
without universally administering carbapenems repre-
sents a challenge. However, using clinical prediction tools 
which identify patients at high risk for ESBL-E infection 
could be an option [38]. Also, shortening the turnaround 
time of resistance results might mitigate the deleterious 
effect of inappropriate empiric therapy.
Limitations of our study are the retrospective design 
and the lack of travel history, which in the healthy popula-
tion is among the most important risk factors for ESBL-E 
colonization and infection. However, travel is unlikely to 
have a major impact in this particular patient population. 
Because most of our study participants were RTR, the 
results might not be applicable to other SOT recipients. 
The sample size for the analysis of unfavourable outcome 
might have been too small to draw valid conclusions. In 
particular, our study might have been underpowered to 
evaluate the impact of being a RTR (compared to other 
SOT recipients), of infections with K. pneumoniae (vs. 
E. coli), or of treatment with carbapenems, which were 
all marginally associated with unfavourable outcome 
in univariate analysis. Also, molecular analysis of caus-
ing pathogens, which could shed light on the molecular 
epidemiology of ESBL-E in our geographic area includ-
ing the presence of E. coli ST131 or healthcare-associ-
ated K. pneumoniae clones, was not performed. Further, 
using ESC-resistance as a proxy for ESBL-production is 
debatable. However, in the antibiotic resistance report of 
the ECDC from 2016, 89% of ESC-resistant E. coli were 
ESBL-producers [39]. Last, appropriateness of antibiotic 
therapy was defined in a rather conservative way, catego-
rizing treatment with piperacillin/tazobactam as inap-
propriate also in non-bacteremic urinary tract infections.
Conclusions
To conclude, ESBL-production among non-E. coli 
Enterobacterales has steadily been increasing among 
Swiss SOT-recipients in recent years. The role of resist-
ant high-risk clones in this worrisome trend remains 
unknown. The only modifiable factor associated with 
the occurrence of ESBL-producing pathogens in our 
study was antibiotic pre-treatment, calling for action 
to strengthen antibiotic stewardship programs in this 
setting. Also, improving appropriateness of empiric 
antibiotic treatment might be an important measure 
to reduce unfavourable outcome, which occurred in 
almost half of SOT-recipients with ESBL-E infections.
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